What Happened?
Shares of medical device company Artivion (NYSE:AORT) fell 5.8% in the morning session after the company reported mixed fourth-quarter 2025 financial results, with revenues falling short of analyst expectations.
The medical device company's revenue for the quarter was $116 million, a 19.2% increase from the prior year, but it slightly missed Wall Street's forecasts. Artivion's non-GAAP profit of $0.17 per share was in line with consensus estimates. While the quarterly results were mixed, the company provided a bright spot with its outlook. Full-year revenue guidance for 2026 came in 1% above analysts’ estimates at the midpoint, and its EBITDA forecast also topped expectations. Despite the positive guidance, investors appeared to focus on the top-line miss for the quarter, leading to a decline in the share price.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Artivion? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Artivion’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 20.3% on the news that it reported strong second-quarter 2025 earnings that surpassed analyst expectations and raised its full-year guidance. The company's revenue for the quarter grew 15.3% year-over-year to $113 million, beating Wall Street's estimates. Its non-GAAP profit of $0.24 per share was also 92% above consensus forecasts, showcasing significant bottom-line strength. Buoyed by the strong performance, Artivion lifted its full-year revenue guidance to a midpoint of $439 million. The results also revealed a marked improvement in cash generation, as its free cash flow margin expanded to 10.4%, up from 3.7% in the same quarter last year. This comprehensive beat and positive outlook fueled investor optimism, leading to the stock's jump.
Artivion is down 15.3% since the beginning of the year, and at $37.65 per share, it is trading 21% below its 52-week high of $47.63 from November 2025. Investors who bought $1,000 worth of Artivion’s shares 5 years ago would now be looking at an investment worth $1,507.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.